RAD CR details:4c for instos, 5c for Big pharma and the rumours...

RAD CR details:

4c for instos, 5c for Big pharma and the rumours were correct, 400% dilution


Radiopharm Theranostics completes A$70 million placement
• Radiopharmaceutical industry leader, Lantheus Holdings, Inc., has agreed to make an
initial strategic equity investment of A$7.5m at A$0.05 per share, which represents a
47% premium to last closing price of A$0.034 on 19 June 2024
• Two Tranche Placement to raise an additional A$62.5m, taking total amount raised
under the placement to A$70.0m
• Offer price for shares issued under the balance of the placement of A$0.04
represents an 18% premium to the last closing price
• Participation from leading international institutional investors including US specialist
healthcare investors
• Net proceeds are expected to fully fund the current clinical programs until the end of
2026
• Executive Chair, Paul Hopper, to participate in the placement with A$3.0 million
investment, subject to shareholder approval
• Option for Lantheus to invest a further A$7.5m within 6 months on the same terms
• Lantheus will also secure rights to two early preclinical assets in exchange for an
A$3m upfront payment pursuant to a transfer and development agreement